BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7907636)

  • 1. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.
    Bannerji R; Arroyo CD; Cordon-Cardo C; Gilboa E
    J Immunol; 1994 Mar; 152(5):2324-32. PubMed ID: 7907636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
    Xiang J; Moyana T
    Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
    Frey AB
    J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
    Frey AB; Cestari S
    Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK 1+ CD4- CD8- alphabeta T cells in the peritoneal cavity: specific T cell receptor-mediated cytotoxicity and selective IFN-gamma production against B cell leukemia and myeloma cells.
    Sugie T; Kubota H; Sato M; Nakamura E; Imamura M; Minato N
    J Immunol; 1996 Nov; 157(9):3925-35. PubMed ID: 8892624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model.
    Doolan DL; Hoffman SL
    J Immunol; 1999 Jul; 163(2):884-92. PubMed ID: 10395683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.